Multifunctional drug delivery system for cancer treatment antibodies
Summary
USPTO published patent application US20260091125A1 for a multifunctional drug delivery system using inorganic core particles conjugated to antibodies for cancer treatment. The system delivers distinct immunoglobulins to cancerous cells and tissues outside the brain via four-linker architecture. Application filed January 12, 2023; granted Application No. 18865714.
What changed
USPTO published patent application US20260091125A1 on April 2, 2026, for a multifunctional delivery system comprising an inorganic core particle conjugated through four linkers: two polymeric linkers to distinct immunoglobulins, a penetration enhancing moiety, and a capping spacer. The system targets cancerous cells and tissues outside the brain. CPC classifications include A61K 47/6929, A61K 47/62, A61K 47/6851, and A61P 35/00. Inventors include Revital Mandil Levin, Oshra Betzer, Yuval Sagiv, Adam Antebi, and Rachela Popovtzer.\n\nPatent applications do not create immediate compliance obligations. Pharmaceutical companies and drug manufacturers developing antibody-based cancer therapies should monitor this application's examination progress as it may indicate competitive landscape developments in targeted delivery technology. No action is required at this time.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MULTIFUNCTIONAL DELIVERY SYSTEM AND USES THEREOF
Application US20260091125A1 Kind: A1 Apr 02, 2026
Inventors
Revital MANDIL LEVIN, Oshra BETZER, Yuval SAGIV, Adam ANTEBI, Rachela POPOVTZER
Abstract
The invention provides multifunctional system for the synchronized delivery of distinct immunoglobulins, in particular antibodies and antibody fragments to specific cancerous cells and tissues located outside of the brain. The multifunctional system is based on an inorganic core particle which is conjugated through a first polymeric linker to a first immunoglobulin; through a second polymeric linker to a second immunoglobulin; through a third polymeric linker to a penetration enhancing moiety; and to a fourth, monofunctional capping linker or spacer. Further provided are a process for preparation of the multifunctional system, pharmaceutical compositions comprising the multifunctional system and uses thereof in therapeutic and/or diagnostic methods.
CPC Classifications
A61K 47/6929 A61K 47/62 A61K 47/6851 A61P 35/00
Filing Date
2023-01-12
Application No.
18865714
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.